Naomi Fujioka, MD, discusses the clinical implications of the PACIFIC trial in NSCLC treatment and additional questions that are informing planned and ongoing trial designs in stage III disease.
Single-agent atezolizumab extended overall survival compared with chemotherapy as a frontline treatment for patients with advanced nonsquamous and squamous non–small cell lung cancer and high PD-L1 expression, according to topline findings from the phase III IMpower110 trial.
Robert A. Kratzke, MD discusses the excitement surrounding immunotherapy and the work being done with biomarkers to assist in making optimal treatment decisions in lung cancer.
The addition of atezolizumab (Tecentriq) to carboplatin and nab-paclitaxel (Abraxane) showed a clinical overall survival benefit among a subgroup of patients with advanced squamous non–small cell lung cancer.
Treatment with nivolumab (Opdivo) was associated with a 5-year overall survival rate of 13.4% compared with 2.6% with docetaxel in patients with previously treated non–small cell lung cancer.
Patients with untreated extensive-stage small cell lung cancer had statistically significant improvement in overall survival when the PD-L1 inhibitor durvalumab (Imfinzi) was added to chemotherapy.
The European Commission has approved atezolizumab for use in combination with carboplatin and nab-paclitaxel for the first-line treatment of adult patients with advanced, nonsquamous non–small cell lung cancer.
The European Commission has approved atezolizumab for use in combination with carboplatin and etoposide for the frontline treatment of adult patients with extensive-stage small cell lung cancer, according to Roche (Genentech) the developer of the PD-L1 inhibitor.
Manish Patel, DO, discusses advances and remaining questions with chemoimmunotherapy combinations in nonsquamous metastatic non–small cell lung cancer.
The FDA has extended the review period for a supplemental biologics license application for atezolizumab for use in combination with carboplatin and nab-paclitaxel as a first-line treatment for patients with metastatic nonsquamous non–small cell lung cancer who do not have EGFR or ALK aberrations.